CLL Treatment Landscape: Overview of BTK Inhibitors

Investigators found certain classes of prescriptions were also associated with outcomes, though they do not believe the association is necessarily a causal one.

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

While physical activity was linked with improved quality of life (QOL), the majority of patients are not given the recommendation from their doctor.

TP53 mutations can have a significant impact on the prognosis of diseases like chronic lymphocytic leukemia, but their effect can vary based on numerous factors.

Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) treated with venetoclax plus obinutuzumab experienced significantly higher rates of serious infections compared with those receiving zanubrutinib, according to real-world data.